Technical Trend Overview and Momentum Shift
The latest technical assessment reveals that Dr Reddys Laboratories has moved from a mildly bearish stance to a more pronounced bearish trend. The daily moving averages have turned bearish, reflecting a downward pressure on the stock price in the short term. This shift is corroborated by the weekly MACD indicator, which remains bearish, while the monthly MACD is mildly bearish, indicating that momentum is weakening across multiple timeframes.
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral zones. This suggests that while the stock is not yet oversold, it lacks the bullish momentum required to trigger a reversal. Bollinger Bands on weekly and monthly charts also indicate a mildly bearish outlook, with the price likely to face resistance near the upper band and potential support near the lower band.
Moving Averages and KST Indicator Insights
Daily moving averages have turned bearish, signalling that the stock’s short-term trend is weakening. This is a critical observation for traders who rely on moving average crossovers to time entries and exits. Meanwhile, the KST (Know Sure Thing) indicator presents a mixed picture: bearish on the weekly timeframe but bullish on the monthly. This divergence suggests that while short-term momentum is negative, longer-term trends may still hold some upside potential, though caution is warranted.
Dow Theory assessments align with this cautious stance, showing a mildly bearish trend on the weekly chart and no clear trend on the monthly chart. The On-Balance Volume (OBV) indicator is bearish on the weekly scale, indicating that selling pressure is outweighing buying interest recently, though monthly OBV remains neutral.
Price Action and Volatility Context
Dr Reddys Laboratories closed at ₹1,175.00, a slight increase from the previous close of ₹1,174.00. The stock’s intraday range was between ₹1,162.75 and ₹1,175.00, reflecting limited volatility on the day. The 52-week high stands at ₹1,414.40, while the 52-week low is ₹1,080.05, placing the current price closer to the lower end of its annual range. This proximity to the lower band may attract some bargain hunters, but the prevailing technical signals counsel prudence.
Comparative Returns and Market Context
When compared with the broader Sensex index, Dr Reddys Laboratories has underperformed over the medium term. The stock delivered a 2.68% return over the past week, outperforming the Sensex’s 1.32% gain. However, over the last month, the stock declined sharply by 14.16%, while the Sensex rose by 0.86%. Year-to-date, the stock’s return of -7.56% closely mirrors the Sensex’s -7.35%, indicating sectoral or company-specific headwinds.
Longer-term returns show a more mixed picture. Over one year, the stock’s return of -1.85% slightly outperforms the Sensex’s -1.97%. Yet, over three and five years, Dr Reddys Laboratories has lagged significantly, with returns of 4.02% and 22.77% respectively, compared to the Sensex’s 20.14% and 45.46%. Over a decade, the stock has delivered a robust 95.71% gain, though still trailing the Sensex’s 181.19% growth, underscoring the challenges faced in maintaining consistent outperformance.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Mojo Score and Grade Revision
MarketsMOJO’s proprietary scoring system currently assigns Dr Reddys Laboratories a Mojo Score of 30.0, categorising the stock with a Sell grade. This represents a downgrade from the previous Hold rating, effective from 13 July 2026. The downgrade reflects the deteriorating technical indicators and the stock’s weakening momentum, signalling caution for investors. The mid-cap classification of the company further emphasises the need for careful risk management given the sector’s volatility.
Sectoral and Industry Considerations
Operating within the Pharmaceuticals & Biotechnology sector, Dr Reddys Laboratories faces sector-specific challenges including regulatory scrutiny, pricing pressures, and competitive innovation cycles. The sector’s overall performance has been mixed, with some peers showing resilience while others struggle with patent expiries and R&D setbacks. The stock’s technical weakness may partly reflect these broader industry headwinds, compounded by company-specific factors.
Investor Implications and Outlook
From a technical perspective, the bearish signals across multiple indicators suggest that investors should exercise caution. The daily moving averages and weekly MACD indicate a continuation of downward momentum, while neutral RSI readings imply limited immediate reversal potential. The divergence in KST readings between weekly and monthly timeframes suggests that any recovery may be slow and tentative.
Given the stock’s recent underperformance relative to the Sensex and its downgrade to a Sell grade, investors may consider reducing exposure or waiting for clearer signs of technical recovery before initiating new positions. Those with a longer-term horizon might monitor the monthly KST and Bollinger Bands for early indications of trend stabilisation.
Holding Dr Reddys Laboratories Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Technical Signals
In summary, Dr Reddys Laboratories is currently navigating a challenging technical landscape. The weekly MACD and OBV indicators are bearish, daily moving averages confirm short-term weakness, and Bollinger Bands suggest mild bearishness on weekly and monthly scales. The absence of strong RSI signals indicates a lack of momentum to reverse the downtrend imminently. The mixed KST readings highlight the complexity of the stock’s technical profile, with short-term caution balanced by some longer-term bullish potential.
Investors should weigh these technical factors alongside fundamental and sectoral considerations before making decisions. The downgrade to a Sell grade by MarketsMOJO underscores the need for vigilance and disciplined risk management in the current environment.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
